SE0103424D0 - Pharmaceutical formulation - Google Patents

Pharmaceutical formulation

Info

Publication number
SE0103424D0
SE0103424D0 SE0103424A SE0103424A SE0103424D0 SE 0103424 D0 SE0103424 D0 SE 0103424D0 SE 0103424 A SE0103424 A SE 0103424A SE 0103424 A SE0103424 A SE 0103424A SE 0103424 D0 SE0103424 D0 SE 0103424D0
Authority
SE
Sweden
Prior art keywords
drug
sub
alpha
relates
pharmaceutical formulation
Prior art date
Application number
SE0103424A
Other languages
English (en)
Inventor
Nicola Bateman
Julie Cahill
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0103424A priority Critical patent/SE0103424D0/sv
Publication of SE0103424D0 publication Critical patent/SE0103424D0/sv
Priority to IL16130602A priority patent/IL161306A0/xx
Priority to KR1020047005493A priority patent/KR20050035163A/ko
Priority to CNA028203747A priority patent/CN1571658A/zh
Priority to HU0401369A priority patent/HUP0401369A3/hu
Priority to EP02770069A priority patent/EP1439823A1/en
Priority to ARP020103826A priority patent/AR036877A1/es
Priority to BR0213248-6A priority patent/BR0213248A/pt
Priority to MXPA04003520A priority patent/MXPA04003520A/es
Priority to PL02368226A priority patent/PL368226A1/xx
Priority to CA002462219A priority patent/CA2462219A1/en
Priority to US10/492,629 priority patent/US20060058381A1/en
Priority to RU2004115023/15A priority patent/RU2004115023A/ru
Priority to PCT/GB2002/004621 priority patent/WO2003032950A1/en
Priority to JP2003535754A priority patent/JP3639587B2/ja
Priority to ZA200402729A priority patent/ZA200402729B/xx
Priority to NO20041485A priority patent/NO20041485L/no
Priority to IS7219A priority patent/IS7219A/is
Priority to CO04043957A priority patent/CO5580755A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE0103424A 2001-10-15 2001-10-15 Pharmaceutical formulation SE0103424D0 (sv)

Priority Applications (19)

Application Number Priority Date Filing Date Title
SE0103424A SE0103424D0 (sv) 2001-10-15 2001-10-15 Pharmaceutical formulation
JP2003535754A JP3639587B2 (ja) 2001-10-15 2002-10-11 医薬製剤
MXPA04003520A MXPA04003520A (es) 2001-10-15 2002-10-11 Formulacion farmaceutica que comprende (r)-bicalutamida.
CA002462219A CA2462219A1 (en) 2001-10-15 2002-10-11 Pharmaceutical formulation comprising (r) -bicalutamide
CNA028203747A CN1571658A (zh) 2001-10-15 2002-10-11 包含(r)－比卡鲁胺的药物制剂
HU0401369A HUP0401369A3 (en) 2001-10-15 2002-10-11 Pharmaceutical formulation comprising (r)-bicalutamide, process for its preparation and use thereof
EP02770069A EP1439823A1 (en) 2001-10-15 2002-10-11 Pharmaceutical formulation comprising (r)-bicalutamide
ARP020103826A AR036877A1 (es) 2001-10-15 2002-10-11 Formulacion farmaceutica
BR0213248-6A BR0213248A (pt) 2001-10-15 2002-10-11 Formulação farmacêutica, dose farmacêutica, dispersão sólida de um polìmero entérico, métodos para o tratamento de cãncer de próstata e/ou para a redução do risco de cancer de próstata em um paciente, para aumentara biodisponibilidade e a estabilidade em armazenamento de 4'-ciano-alfa',alfa',alfa' -trifluoro-3-(4-fluorofenilsilfonil)-2-hidróxi-2-metil propiono-m-toluidida, e para a preparação de uma formulação farmacêutica, e, usos de 4'-ciano-alfa',alfa',alfa'-trifluoro-3-(4-fluorofenilsu lfonil -2-hidróxi-2-metilpropiono-m-toluidida e de um polìmero entérico
IL16130602A IL161306A0 (en) 2001-10-15 2002-10-11 Pharmaceutical formulation comprising (r)-bicalutamide
PL02368226A PL368226A1 (en) 2001-10-15 2002-10-11 Pharmaceutical formulation comprising (r) -bicalutamide
KR1020047005493A KR20050035163A (ko) 2001-10-15 2002-10-11 (ｒ)-비칼루타미드를 포함하는 약학적 제제
US10/492,629 US20060058381A1 (en) 2001-10-15 2002-10-11 Pharmaceutical formulation comprising (r)-bicalitamide
RU2004115023/15A RU2004115023A (ru) 2001-10-15 2002-10-11 Фапмацевтическая композиция, содержащая (r)-бикалутамид
PCT/GB2002/004621 WO2003032950A1 (en) 2001-10-15 2002-10-11 Pharmaceutical formulation comprising (r) -bicalutamide
ZA200402729A ZA200402729B (en) 2001-10-15 2004-04-07 Pharmaceutical formulation comprising (R) -bicalutamide.
NO20041485A NO20041485L (no) 2001-10-15 2004-04-13 Farmasoytisk formulering omfattende (R)-bicalutamid
IS7219A IS7219A (is) 2001-10-15 2004-04-14 Lyfjablanda sem inniheldur (R) -bíkalútamíð
CO04043957A CO5580755A2 (es) 2001-10-15 2004-05-12 Formulacion farmaceutica comprendiendo (r)-bicalutamida

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0103424A SE0103424D0 (sv) 2001-10-15 2001-10-15 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
SE0103424D0 true SE0103424D0 (sv) 2001-10-15

Family

ID=20285650

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0103424A SE0103424D0 (sv) 2001-10-15 2001-10-15 Pharmaceutical formulation

Country Status (19)

Country Link
US (1) US20060058381A1 (sv)
EP (1) EP1439823A1 (sv)
JP (1) JP3639587B2 (sv)
KR (1) KR20050035163A (sv)
CN (1) CN1571658A (sv)
AR (1) AR036877A1 (sv)
BR (1) BR0213248A (sv)
CA (1) CA2462219A1 (sv)
CO (1) CO5580755A2 (sv)
HU (1) HUP0401369A3 (sv)
IL (1) IL161306A0 (sv)
IS (1) IS7219A (sv)
MX (1) MXPA04003520A (sv)
NO (1) NO20041485L (sv)
PL (1) PL368226A1 (sv)
RU (1) RU2004115023A (sv)
SE (1) SE0103424D0 (sv)
WO (1) WO2003032950A1 (sv)
ZA (1) ZA200402729B (sv)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK10722003A3 (sk) * 2001-02-27 2004-02-03 Astrazeneca Ab Farmaceutická formulácia obsahujúca bicalutamid v pevnej disperzii s enterickým polymérom a jej použitie
DK3366283T3 (da) 2004-01-20 2021-11-22 Novartis Ag Direkte sammenpresningsformulering og fremgangsmåde
WO2006090129A2 (en) * 2005-02-23 2006-08-31 Astrazeneca Ab Bicalutamide for delivering increasing steady state plasma levels
US20100047338A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US20080045600A1 (en) * 2006-08-17 2008-02-21 Gawande Rahul S Bicalutamide compositions
AU2010210422A1 (en) 2009-02-05 2011-08-18 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
CN101987086B (zh) * 2009-08-03 2012-07-18 北京化工大学 一种超细比卡鲁胺口服片剂及其制备方法
JP2014523445A (ja) * 2011-07-18 2014-09-11 トーカイ ファーマシューティカルズ，インク． 前立腺癌を処置するための新規な組成物及び方法
EP4450130A3 (en) 2012-09-11 2025-01-08 Medivation Prostate Therapeutics LLC Formulations of enzalutamide
KR20150127720A (ko) 2013-03-14 2015-11-17 유니버시티 오브 매릴랜드, 발티모어 안드로겐 수용체 하향 조절제 및 그의 용도
WO2015023710A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
RS66323B1 (sr) * 2014-12-05 2025-01-31 Aragon Pharmaceuticals Inc Sastavi protiv raka
MX381829B (es) 2014-12-05 2025-03-13 Aragon Pharmaceuticals Inc Composiciones anticancerígenas.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629237A (en) * 1968-09-12 1971-12-21 Shinetsu Chemical Co Compositions useful as enteric coatings and method for preparing acid phthalates of cellulose ethers for them
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
ATE28864T1 (de) * 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
US4946686A (en) * 1987-09-24 1990-08-07 Merck & Co., Inc. Solubility modulated drug delivery system
EP0580860B2 (en) * 1991-04-16 2004-12-15 Nippon Shinyaku Company, Limited Method of manufacturing solid dispersion
EP0748220A4 (en) * 1994-01-21 1997-09-10 Sepracor Inc METHOD AND COMPOSITIONS FOR TREATING ANDROGEN-DEPENDENT DISEASES USING OPTICALLY PURE R - (-) CASODEX
SK10722003A3 (sk) * 2001-02-27 2004-02-03 Astrazeneca Ab Farmaceutická formulácia obsahujúca bicalutamid v pevnej disperzii s enterickým polymérom a jej použitie
WO2002080902A1 (en) * 2001-04-02 2002-10-17 Astrazeneca Ab Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp

Also Published As

Publication number Publication date
WO2003032950A1 (en) 2003-04-24
JP2004521963A (ja) 2004-07-22
HUP0401369A2 (hu) 2004-11-29
AR036877A1 (es) 2004-10-13
MXPA04003520A (es) 2004-07-23
IL161306A0 (en) 2004-09-27
ZA200402729B (en) 2005-01-13
JP3639587B2 (ja) 2005-04-20
PL368226A1 (en) 2005-03-21
NO20041485L (no) 2004-04-13
US20060058381A1 (en) 2006-03-16
HUP0401369A3 (en) 2006-05-29
CO5580755A2 (es) 2005-11-30
KR20050035163A (ko) 2005-04-15
IS7219A (is) 2004-04-14
EP1439823A1 (en) 2004-07-28
CA2462219A1 (en) 2003-04-24
BR0213248A (pt) 2004-09-28
RU2004115023A (ru) 2005-04-10
CN1571658A (zh) 2005-01-26

Similar Documents

Publication Publication Date Title
EE200300476A (et) 4-tsüanotrifluoro-3-(4-fluorofenüülsulfonüül)-2-hüdroksü-2-metüülpropiono-m-toluidii di ja PVP-d sisaldav tahke farmatseutiline kompositsioon
WO2002067893A3 (en) Pharmaceutical formulation comprising bicalutamide
SE0103424D0 (sv) Pharmaceutical formulation
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
CY1109681T1 (el) Υποκατεστημενα παραγωγα κιναζολινης ως αναστολεις των κινασων aurora
BR0113757A (pt) Derivados de quinolinona como inibibores de tirosina quinase
ATE319447T1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
BR0207316A (pt) Derivados de epotilona para o tratamento de tumores refratários
NO20034204D0 (no) Farmasöytiske kombinasjoner til behandling av kreft
DK1256339T3 (da) Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdom
BR0208373A (pt) Inibidores da tirosina cinase
BRPI0410563A (pt) derivados de pirazol-quinazolina processo para sua preparação e seu uso como inibidores de quinase
HU0102039D0 (en) Use of paclitaxel stabilized with albumin for the preparation of pharmaceutical compositions treating solid tumors and the pharmaceutical compositions obtained thereby
IS6329A (is) Lyf til að meðhöndla illkynja æxli
ATE409185T1 (de) Chinazolin derivate
ATE478662T1 (de) Arzneilösungen enthaltend modafinilverbindungen
SE0103839D0 (sv) Pharmaceutical formulation & product
NO20023486L (no) Forbindelser av pyrroltypen, perapater inneholdende forbindelser samt deres anvendelse for behandling av cancer- ogvirale sykdommer
SE0102440D0 (sv) New compound
DE60222383D1 (de) Medikament zur verabreichung von amifostin und verwandten wirkstoffen
PL368686A1 (en) Novel aminobenzoephenones
SE0103838D0 (sv) Pharmaceutical formulation & product
NO20026032D0 (no) Farnesyltransferasehemmende 1,2-annelert kinolinenantiomer
SE0102887D0 (sv) New formulation